WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/11147/7150
Browse
20 results
Search Results
Now showing 1 - 10 of 20
Article Citation - WoS: 139Granulocytic Sarcoma: a Systematic Review(e-Century Publishing Corporation, 2013) Yılmaz, Asu Fergün; Saydam, Güray; Şahin, Fahri; Baran, YusufGranulocytic sarcoma also called myeloid sarcoma is an extramedullary tumor of immature granulocytic cells. It is a rare entity, and mostly accompanied by acute myeloid leukemia. It is observed during the course of myeloproliferative disorders especially in chronic myeloid leukemia and myelodysplastic syndromes. In some rare circumstances, it is detected before clinical signs of leukemia or other diseases. When the bone marrow biopsy reveals no other hematologic malignancies, the granulocytic sarcoma is described as nonleukemic, primary or isolated. It is observed at any part of the body but the most common locations are soft tissues, bone, peritoneum and lymph nodes. Presenting signs or symptoms are mainly due to mass effect of the tumor and dysfunction of the organ, or the tissue that is affected. The diagnosis is performed by biopsy of the tumor. The tumor consists of immature granulocytic cells, which could be documented by H&E, immunohistochemistry, and flow cytometric methods. Fluorescence in-situ hybridization and molecular analysis are also performed. The optimal time and type of treatment is not clear. Surgery could be an option especially for tumors, which cause organ dysfunction and/or obstruction. Systemic treatment should be considered in all patients because without systemic treatment, relapses and progression to acute myeloid leukemia is the ultimate fate of the disease in many cases. Cytarabine-containing remission-induction chemotherapies have been the most applied therapeutic strategies, but it is not clear whether the consolidation therapies are required or not, and what kind of regimens are appropriate. The role of hematopoietic stem cell transplantation (HSC) as a consolidation regimen is not clear, but, after the relapse of the disease with or without bone marrow involvement, HSC transplantation should be considered in suitable patients after the reinduction performed by AML chemotherapies. There is only limited data about the role of radiotherapy in these patients. It could be used in patients with relapsed disease, organ dysfunction which should be quickly relieved and inadequate response to chemotherapy. The effect of radiotherapy on overall survival is not known. New prospective studies and clinical trials are needed to generate guidelines for the treatment of primary granulocytic sarcomas.Article Citation - WoS: 15Changes in Molecular Biology of Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor Era(e-Century Publishing Corporation, 2013) Cömert, Melda; Baran, Yusuf; Saydam, GürayChronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by a reciprocal translocation between long arms of chromosomes 9 and 22 t(9; 22) that generates the BCR-ABL fusion gene. If left untreated, newly diagnosed chronic phase CML patients finally progress to accelerated and blastic phase. After the introduction of tyrosine kinase inhibitors (TKIs), treatment strategies of CML changed dramatically. However, the development of resistance to TKIs started to create problems over time. In this review, the current information about CML biology before and after imatinib mesylate treatment is summarized.Article Citation - WoS: 16Cumulative Clinical Experience From a Decade of Use: Imatinib as First-Line Treatment of Chronic Myeloid Leukemia(Dove Medical Press Ltd., 2012) Baran, Yusuf; Saydam, GürayChronic myeloid leukemia (CML) is a malignant disease that originates in the bone marrow and is designated by the presence of the Philadelphia (Ph+) chromosome, a translocation between chromosomes 9 and 22. Targeted therapy against CML commenced with the development of small-molecule tyrosine kinase inhibitors (TKIs) exerting their effect against the oncogenic breakpoint cluster region (BCR)-ABL fusion protein. Imatinib emerged as the first successful example of a TKI used for the treatment of chronic-phase CML patients and resulted in significant improvements in response rate and overall survival compared with previous treatments. However, a significant portion of patients failed to respond to the therapy and developed resistance against imatinib. Second-generation TKIs nilotinib and dasatinib were to have higher efficiency in clinical trials in imatinib- resistant or intolerant CML patients com pared with imatinib. Identification of novel strategies such as dose escalation, drug combination therapy, and use of novel BCR-ABL inhibitors may eventually overcome resistance against BCR-ABL TKIs. This article reviews the history of CML, including the treatment strategies used prediscovery of TKIs and the preclinical and clinical data obtained after the use of imatinib, and the second-generation TKIs developed for the treatment of CML.Conference Object The Effects of Ceramide, Glucosylceramide and Sphingosine 1 Phosphate in Resveratrol Induced Cell Death in Hl60 Acute Promyelocytic Leukemia Cells(Ferrata Storti Foundation, 2009) Çakır, Zeynep; Saydam, Güray; Şahin, Fahri; Baran, Yusuf[No abstract available]Conference Object Citation - WoS: 1Increasing Intracellular Generation or Accumulation of Ceramides Increased Cytotoxic Effects of Resveratrol in Human K562 Chronic Myeloid Leukemia Cells(Ferrata Storti Foundation, 2009) Kartal Yandım, Melis; Saydam, Güray; Şahin, Fahri; Baran, Yusuf[No abstract available]Conference Object Ceramides Regulate Resveratrol-Induced Apoptosis in Human Acute Promyelocytic and Chronic Myeloid Leukemia Cells(Ferrata Storti Foundation, 2010) Baran, Yusuf; Kartal, Melis; Çakır, Zeynep; Saydam, Güray; Şahin, Fahri[No abstract available]Conference Object Gene Expression Profiles in Resveratrol Applied Acute Promyelocytic Leukemia Cells(Ferrata Storti Foundation, 2010) Baran, Yusuf; Çakır, Zeynep; Can, Geylani; Saydam, Güray; Şahin, Fahri[No abstract available]Conference Object Gene Expression Profiles in Resveratrol-Induced Cell Death in Acute Promyelocytic Leukemia Cells(Elsevier Ltd., 2010) Çakır, Zeynep; Can, Geylani; Saydam, Güray; Şahin, Fahri; Baran, Yusuf[No abstract available]Conference Object Zoledronate Induces Apoptosis Via Effecting on Stat Pathway in Chronic Myeloid Leukemia Cells(Ferrata Storti Foundation, 2012) Saydam, Güray; Kiper, Hatice Demet; Tezcanlı, Burçin; Selvi, Nur; Avcı, Çığır Biray; Baran, Yusuf; Şahin, Fahri[No abstract available]Conference Object Enalapril Maleate Has Cytotoxıc Effect in Hl 60 Leukemic Cells by Altering Stat Signaling Pathway(Ferrata Storti Foundation, 2012) Şahin, Fahri; Purçlutepe, Özlem; Kiper, Hatice Demet; Tezcanlı, Burçin; Selvi, Nur; Biray Avcı, Çığır; Baran, Yusuf; Saydam, Güray[No abstract available]